The EPIC-Norfolk Study

 

Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report.

Verbeek R, Boyer M, Boekholdt SM, Hovingh GK, Kastelein JJ, Wareham N, Khaw KT, and Arsenault BJ

Arteriosclerosis, thrombosis, and vascular biology. Jun 2016

(DOI : 10.1161/ATVBAHA.116.307995)

---